On the stock market since 1991, it operates in the world of health and science. It has 15,410 employees. Now — the numbers.
This is an established company with proven profits.
The biggest line carries real weight, but it doesn’t decide everything on its own.
If every debt were paid off today, $5.9B would still be left in the vault — a solid cushion for hard times.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Debt is low and cash is strong; the finances stand solid.
Clearly above the class average — a step short of the very top.
This grade is a blend: the profit side is strong, the sales tempo slow.
Clearly above the class average — a step short of the very top.
No real weak spot in any of the five subjects — a balanced report card.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Executive Buying: The trades send no strong signal of confidence.
The stock trades 31% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 31% — still a thick cushion, though costs have been eating into it lately.
There is $8.6B in the vault; even if every debt were paid off, $5.9B would remain.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
No clear buy-side message is coming from the executive floor. Council score: 3/10.
On our five-subject report card, REGN sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: REGN is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.